I. Background | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tumor mutational burden (TMB) shows great promise as a biomarker for immuno-oncology (I-O) therapy response, but progress is hindered by the lack of a standardized TMB measurement by targeted NGS panels, and an absence of TMB reference materials.
計(jì)算數(shù)據(jù)下載:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||